Press Release
DNA template manufacturing: Benefit from our cooperation with Touchlight
A critical starting material for mRNA manufacturing is template DNA. Our partner Touchlight has developed a cell-free enzymatic DNA manufacturing process, with advantages of speed, quality, capacity, and scalability. Due to the collaboration agreement between Lonza and Touchlight our customers can get seamless access to Touchlight’s doggybone DNA technology.
Learn moreOur location
Geleen – new mRNA/LNP services and manufacturing
At our site in Geleen, Lonza operates cell and gene therapy process development and manufacturing, mRNA/LNP process and analytical development labs, as well as clinical cGMP capabilities. The facility includes more than 30,000 square feet of laboratory, cGMP manufacturing and office space. The expansion supports the manufacturing of non-GMP product suitable for formulation development and toxicology studies, as well as cGMP product for early and late-stage clinical trials. The expanded development services at the Geleen (NL) site are available with cGMP readiness scheduled in the first quarter 2024.
cGMP defines the rigorous regulatory standards we follow to ensure mRNA manufacturing is consistently controlled. As a leading mRNA CDMO, we adhere to these guidelines to guarantee that every drug product meets the strict quality requirements necessary for safe clinical and commercial use.
We ensure regulatory readiness through well-defined quality systems and comprehensive documentation that adheres to global cGMP guidelines. Our RNA manufacturing processes are designed to meet regulatory expectations, supporting a smooth and predictable progression through clinical phases and commercial launch.
We operate under strict cGMP protocols to ensure total product safety, quality, and traceability. In the field of mRNA production, compliance is the foundation of patient safety and is essential for securing regulatory approval for both clinical trials and large-scale commercial supply.
Consistency is achieved through highly controlled mRNA manufacturing processes, robust in-process monitoring, and strict adherence to validated operating procedures. Detailed batch documentation and release testing ensure that every run within our mRNA production facilities meets your predefined quality specifications.
We manage technology transfer through structured protocols and close collaboration between our development and manufacturing teams. As an integrated mRNA CDMO, we utilize detailed documentation and proven scale-up strategies to ensure a reliable transition from the bench to cGMP production.
